PUBLISHER: The Business Research Company | PRODUCT CODE: 1415732
PUBLISHER: The Business Research Company | PRODUCT CODE: 1415732
“Acute Coronary Syndrome Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on acute coronary syndrome market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for acute coronary syndrome? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The acute coronary syndrome market global report ” from The Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Acute coronary syndrome (ACS) encompasses a spectrum of clinical conditions resulting from a sudden reduction in blood flow to the heart. ACS is characterized by symptoms like chest pain or discomfort (angina), along with indicators of cardiac distress such as shortness of breath and dizziness. The primary objective in treating ACS is to swiftly alleviate symptoms, mitigate heart damage, and prevent potential complications.
There are three main types of acute coronary syndrome such as non-ST-elevation myocardial infarction (NSTEMI), ST-elevation myocardial infarction (STEMI), and unstable angina. NSTEMI denotes a type of heart attack where one or more coronary arteries are partially or completely obstructed, leading to reduced blood supply to the heart muscle. Treatment modalities encompass medications like statins, beta-blockers, ACE inhibitors, anticoagulants, among others. Diagnostic procedures include stress tests, blood tests, various imaging techniques, and more. These treatments can be administered orally or through parenteral routes, and they are employed across a range of end-users including hospitals, specialty clinics, and others.
The acute coronary syndrome market research report is one of a series of new reports from The Business Research Company that provides acute coronary syndrome market statistics, including acute coronary syndrome industry global market size, regional shares, competitors with an acute coronary syndrome market share, detailed acute coronary syndrome market segments, market trends and opportunities and any further data you may need to thrive in the acute coronary syndrome industry. This acute coronary syndrome market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The acute coronary syndrome market size has grown strongly in recent years. It will grow from $9.23 billion in 2023 to $9.86 billion in 2024 at a compound annual growth rate (CAGR) of 6.9%. The growth in the historic period can be attributed to public health initiatives, adoption of telemedicine and remote monitoring, improved emergency medical services, demand for patient education.
The acute coronary syndrome market size is expected to see strong growth in the next few years. It will grow to $12.44 billion in 2028 at a compound annual growth rate (CAGR) of 6.0%. The growth in the forecast period can be attributed to demand for personalized medicine, increase in interventional cardiology, increasing awareness, global aging population. Major trends in the forecast period include advancements in diagnostic tools, integration of health information technology, rapid response systems, technological advancements.
The growth of the acute coronary syndrome market is expected to be fueled by the increasing prevalence of chronic diseases like coronary artery disease, ischemic heart disease, and vascular diseases. Ischemic heart disease, characterized by the narrowing or obstruction of coronary arteries, is one such chronic condition. The treatment of acute coronary syndrome (ACS) focuses on promptly alleviating symptoms, minimizing heart damage, and preventing further complications, especially for patients dealing with conditions like ischemic heart disease and vascular diseases. For instance, in August 2022 a study published in the Journal of the American College of Cardiology highlighted an anticipated rise in all four cardiovascular risk factors among the general U.S. population from 2025 to 2060. Dyslipidemia was projected to increase by 27.6%, while hypertension by 25.1%. The study also noted significant anticipated increases in rates of heart failure (33.4%) and ischemic heart disease (30.7%), followed by heart attacks (16.9%) and strokes (33.8%). This underscores how the prevalence of chronic diseases, including coronary artery disease, ischemic heart disease, and vascular diseases, is a driving force behind the acute coronary syndrome market's growth.
The increasing incidence of cardiac disorders is expected to be a significant driver behind the growth of the acute coronary syndrome market. Cardiac disorders encompass a wide range of medical conditions affecting the heart or blood vessels, including coronary artery disease, heart failure, and arrhythmias. This rise in cardiac disorders plays a pivotal role in acute coronary syndrome (ACS) as it involves conditions where blood flow to the heart muscle is reduced or blocked. This surge in cases is leading to an increased demand for acute coronary syndrome treatments. For instance, in March 2022 a report published by the Office for National Statistics revealed that between 2020 and 2021, there were 19,440 to 20,061 reported deaths due to heart attacks. Furthermore, data from the Centers for Disease Control and Prevention in May 2023 indicated that in the US, 1 in 20 adults aged 20 and older were affected by cardiovascular diseases in 2021. This amounted to 695,000 individuals, with 375,476 of them succumbing to cardiovascular diseases that same year. Hence, the rising incidence of cardiac disorders is a significant force driving the growth of the acute coronary syndrome market.
The growth of the acute coronary syndrome market is expected to face hindrances due to the side effects associated with its treatment. Acute coronary syndrome typically requires a combination of drugs and procedures to restore blood flow and prevent further heart damage. While treatment for acute coronary syndrome is often beneficial, it is also associated with several adverse effects, including bleeding, low blood pressure, and allergic reactions. For instance, in September 2022, Merck & Co. Inc., a US-based pharmaceutical company, highlighted that aspirin, an antiplatelet drug used to reduce short- and long-term mortality risk in acute coronary syndrome patients, may lead to side effects such as gastrointestinal bleeding and ulcers. As a result, the presence of treatment-related side effects presents a challenge to the growth of the acute coronary syndrome market.
The key players in the acute coronary syndrome market are focusing on the development of groundbreaking drugs to advance the treatment of acute coronary syndrome and maintain their market standing. These innovations in drug development have the potential to enhance the effectiveness of ACS treatment, streamlining the process for each patient in terms of time and resources. For instance, in June 2023, AGEPHA Pharma USA LLC, a US-based pharmaceutical company, introduced Lodoco, the first anti-inflammatory atheroprotective cardiovascular treatment approved by the Food and Drug Administration (FDA). This medication is designed to reduce the risk of heart stroke, coronary revascularization, myocardial infarction (MI), and cardiovascular death in adult patients with cardiovascular diseases, including acute coronary syndrome.
In May 2023, Avertix Medical Inc., a US-based company specializing in the development of implantable patient alerting systems for acute coronary syndrome (ACS), entered a merger agreement with BIOS Acquisition Corporation for an approximate sum of $195 million. This strategic merger positions Avertix to enhance its commercial portfolio and further advance its innovative products, providing both patients and healthcare providers with state-of-the-art tools. BIOS Acquisition Corporation is a US-based incorporated blank check company.
Major players in the acute coronary syndrome market are Pfizer Inc., Johnson and Johnson Limited, Siemens AG, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi-Aventis LLC., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., AstraZeneca PLC, Abbott Laboratories, Medtronic PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Co Ltd., Stryker Corporation, GE Healthcare Inc., Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Regeneron Pharmaceuticals Inc., Daiichi Sankyo Company Limited, Terumo Corp., BioMerieux SA, Beckman Coulter Inc., Quidel Corporation, Bio-Rad Laboratories Inc., Biotronik Inc., Randox Laboratories Limited, Nihon Kohden Corporation, Trinity Biotech plc .
North America was the largest region in the acute coronary syndrome market in 2023. The regions covered in acute coronary syndrome report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the acute coronary syndrome market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The acute coronary syndrome market consists of revenues earned by entities by providing various diagnoses through cardiac enzyme tests, blood tests and echocardiograms. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute coronary syndrome market also consists of sales of percutaneous coronary intervention (PCI) drugs and angiotensin-converting enzyme (ACE) inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.